These benefits, together with a past report showing that a small-molecule ACKR3 agonist CCX771 displays anxiolytic-like behavior in mice,2 guidance the strategy of focusing on ACKR3 as a novel strategy to modulate the opioid procedure, which could open new therapeutic avenues for opioid-similar